Skip to main content
TBPH logo

TBPH · Theravance Biopharma, Inc. · Options Chain

Track TBPH — free
$17.01 -0.01 (-0.06%) At close · Sep 11
Market Cap
$883.66M
Shares
51.92M

Options Chain

Underlying $17.01 · at close Sep 11, 2026 Options Calculator

Positioning

Sep 18, 2026 · 6 days to expiry · 24 contracts · mixed daily-bar sessions · Mar 4, 2026–Sep 8, 2026; 16 unknown
Put / call OI
26.42
Put-heavy positioning
Open interest
1,892
as of Sep 10, 2026
Volume
dated and unknown daily-bar sessions
Max pain
$17.50
$0.49 above spot
ATM implied vol
273.8%
market's expected move

Open interest by strike

Calls Puts

Chain

Click any strike for greeks, breakeven and the calculator
OI Vol IV Δ Bid Ask Last Strike Last Bid Ask Δ IV Vol OI
$13.40 $17.00 $0.00 $0.05
$10.90 $14.50 $0.00 $0.05
$8.80 $12.00 $0.00 $0.05
2 $5.70 $9.50 $5.85 $0.41 $0.00 $0.05 36 20
$2.30 $7.00 $0.05 $0.00 $0.05 975 1.8k
151.6% 0.773 $0.10 $4.90 $0.05 $0.00 $0.05 1 5
39 10 $0.00 $0.05 $0.10 $0.40 $0.40 $4.90 -0.462 273.8% 2 8
$0.00 $0.05 $1.00 $5.50 -0.812 130.2%
28 28 $0.00 $0.05 $0.25 $4.80 $8.00
$0.00 $4.80 $7.20 $10.50
$0.00 $4.80 $11.70 $15.50
2 1 $0.00 $0.10 $1.25 $16.70 $20.50
About this data

Each contract's last price, day range and volume belong to the daily-bar session shown in its details; unknown means the source omitted that timestamp. Open interest has its own effective date shown separately; implied volatility and greeks are model values computed when fetched. This chain has mixed daily-bar sessions · Mar 4, 2026–Sep 8, 2026; 16 unknown. Positioning totals are shown only when every returned open-interest value has the same known effective date. Bid and ask are real-time consolidated OPRA readings.

In-the-money strikes are tinted, deepening toward the money, and the bar beside each open-interest figure scales to the heaviest strike shown. Max pain is the listed strike where the most open interest would expire worthless — a positioning reference, not a forecast.

Key facts CIK 1583107 CUSIP G8807B106 13F (30d) 91 filings 90 filers Visit website Investor relations